Canton Strategic Holdings (CNTN) Free Cash Flow (2021 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Free Cash Flow came in at -$7.6 million in Q1 2026, down 183.94% YoY from $9.1 million in Q1 2025, and up 26.88% on a QoQ basis from -$10.4 million in Q4 2025.
Analysis
Canton Strategic Holdings (CNTN) Free Cash Flow (2021 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of Free Cash Flow data on file, last reported at -$7.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 183.94% year-over-year to -$7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.1 million (down 95.79% YoY) and the FY2025 annual result came in at -$16.1 million, down 47.97% from the prior year.
- Free Cash Flow advanced to -$7.6 million in Q1 2026, from -$10.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$892676.0 in Q4 2022 to a low of -$10.4 million in Q4 2025.
- A 5-year average of -$2.9 million and a median of -$2.2 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 11530.96% — and 2025, when it soared 47.57%.
- Tracing CNTN's Free Cash Flow over 5 years: stood at -$892676.0 in 2022, then slumped by 58.56% to -$1.4 million in 2023, then plunged by 114.19% to -$3.0 million in 2024, then slumped by 244.42% to -$10.4 million in 2025, then increased by 26.88% to -$7.6 million in 2026.
- The last three Free Cash Flow figures came in at -$7.6 million (Q1 2026), -$10.4 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | -7.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.00 Mn |
| Mar 31, 2026 | -62.46 Mn |
| Dec 31, 2025 | -10.43 Mn |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Mar 31, 2025 | -2.69 Mn |
| Dec 31, 2024 | -3.03 Mn |
| Sep 30, 2024 | -2.86 Mn |
| Jun 30, 2024 | -2.18 Mn |
| Mar 31, 2024 | -2.83 Mn |
| Dec 31, 2023 | -1.42 Mn |
| Sep 30, 2023 | -908,966.00 |
| Jun 30, 2023 | -1.51 Mn |
| Mar 31, 2023 | -3.46 Mn |
| Dec 31, 2022 | -892,676.00 |
| Sep 30, 2022 | -1.55 Mn |
| Jun 30, 2022 | -1.39 Mn |
| Mar 31, 2022 | -2.73 Mn |
| Dec 31, 2021 | -7,675.00 |
| Sep 30, 2021 | -316,776.00 |